Skip to main content
. 2020 Oct 9;3(6):1083–1099. doi: 10.1021/acsptsci.0c00064

Figure 6.

Figure 6

Efficacy of the NPB and cisplatin combination treatment in ovarian cancer xenografts. Representative images (A) and quantification (B–D) of immunohistochemistry analyses of positive cell (%) in the tumor tissues for selected markers, pBAD (Ser99), Ki67, and TUNEL. Results were statistically analyzed with one-way ANOVA followed by Dunnett’s test post hoc. (Cycle 1) I̵/&P < 0.05, I̵ I̵ /&&P < 0.01 and I̵ I̵ I̵/&&&P < 0.001, compared with the combination-treated group; *P < 0.05, **P < 0.01 and ***P < 0.001, compared with the vehicle-treated group. Cycle 2: #P < 0.05, ##P < 0.01 and ###P < 0.001, compared with the combination-treated group.